talquetamab will improve the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Talquetamab causes cytokine launch syndrome (CRS) which could suppress exercise of CYP enzymes, causing amplified publicity of CYP substrates.Our staff of authorities and employees try relentlessly to produce the